StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Equities research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Trading Down 6.2 %

NASDAQ:AEZS opened at $4.41 on Wednesday. Aeterna Zentaris has a twelve month low of $3.96 and a twelve month high of $12.80. The company has a market capitalization of $7.89 million, a P/E ratio of -0.30 and a beta of 1.56. The firm has a 50-day moving average price of $7.34 and a two-hundred day moving average price of $7.63.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share (EPS) for the quarter. Aeterna Zentaris had a negative return on equity of 83.45% and a negative net margin of 760.32%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.